US 11084865
VEGF antagonist formulations suitable for intravitreal administration
granted A61KA61K38/179A61K38/1793
Quick answer
US patent 11084865 (VEGF antagonist formulations suitable for intravitreal administration) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 64
- CPC classes
- A61K, A61K38/179, A61K38/1793, A61K47/02, A61K47/10